M435-1279 - ≥98% , CAS No.1359431-16-5

CAS: 1359431-16-5 Cat. No.: M649720 Formula: C₁₈H₁₇N₃O₅S₂ Molecular Weight: 419.47

GRADE & PURITY ≥98%

Storage

Protected from light,Store at -80°C

Shipped In

Dry ice packs + Cold packs

Overview

M435-1279 is a UBE2T inhibitor. M435-1279 inhibits the Wnt/β-catenin signaling pathway hyperactivation through blocking UBE2T-mediated degradation of RACK1

In Vitro

M435-1279 (0, 2, 4, 8, 16, 31 μM; 48 h) significantly inhibits the growth of HGC27, AGS, and MKN45 cells. M435-1279 (0, 4, 8, 12, 16, 20 μM) inhibits the cell viability with IC 50 s of 16.8, 11.88, 6.93, 7.76 μM of GES-1, HGC27, MKN45, AGS cells, respectively. M435-1279 (31 nM to 500 μM) binds to UBE2T with a K D value of 50.5 μM. M435-1279 (11.88 μM; 48 h) inhibits the ubiquitination of RACK1 and the hyperactivation of the Wnt/β-catenin pathway. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: HGC27, AGS, and MKN45 cells Concentration: 0, 2, 4, 8, 16, 31 μM Incubation Time: 48 h Result: Inhibited the cell growth. Cell Viability AssayCell Line: HGC27, AGS, and MKN45 cells Concentration: 0, 4, 8, 12, 16, 20 μM Incubation Time: Result: Inhibited the cell viability with IC 50 s of 16.8, 11.88, 6.93, 7.76 μM in GES-1, HGC27, MKN45, AGS cells, respectively.

In Vivo

M435-1279 (5 mg/kg/day; intratumor injection for 18 days) slows the tumor growth . M435-1279 induces higher RACK1 proteins expression, and lower Ki-67 and β-catenin proteins expression in intratumor tumors . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: BALB/C nude mice CDX model (MKN45 tumor size: 75–100 mm 3 ) Dosage: 5 mg/kg/day Administration: Intratumor injection for 18 days Result: Slowed the tumor growth. Induced higher RACK1 proteins expression, and lower Ki-67 and β-catenin proteins expression in intratumor tumors.

Form:Solid

IC50& Target:UBE2T

Specifications

Specifications & Purity

≥98%

Biochemical and Physiological Mechanisms

M435-1279 is a UBE2T inhibitor. M435-1279 inhibits the Wnt/β-catenin signaling pathway hyperactivation through blocking UBE2T-mediated degradation of RACK1.

Storage

Protected from light,Store at -80°C

Shipped In

Dry ice packs + Cold packs

This product requires cold chain shipping. Ground and other economy services are not available.

Action Type

INHIBITOR

Purity

≥98%

Names and Identifiers

Molecular Weight

419.47

Chemical and Physical Properties

• Solubility: DMSO : 50 mg/mL (119.20 mM; Need ultrasonic)

Application Protocols

No validated, item-specific application protocols are provided for this listing.

General HTS/assay workflow (not item-specific)

• Stock preparation: Dissolve in anhydrous DMSO (e.g., 10–50 mg/mL). Vortex and, if needed, sonicate briefly. Pass through a 0.22 µm low-binding filter for sterile assays.
• Plate handling: Aliquot into 96/384-well plates under low light. Seal plates to prevent evaporation; store at −80°C.
• Assay dilution: Add to assay buffer to achieve final 0.1–1% DMSO (verify tolerance). Include vehicle controls and a reference control where available.
• Data integrity: Confirm hits with fresh solid or independent stock; perform dose–response (8–12 points) and counterscreens to flag interference (fluorescence, redox, aggregation).

These steps are provided as general research guidance only; adapt to your assay and institutional SOPs.

Biological Roles

Item-specific biological function, target class, and pathway engagement are not provided for this compound.

General considerations for small-molecule library members (not item-specific)

• Potential roles may range from enzyme modulation to receptor interaction or pathway perturbation, depending on chemotype and physicochemical properties.
• Prior to biological testing, confirm identity and purity, establish a non-precipitating working concentration, and perform orthogonal counterscreens to exclude assay interference (e.g., fluorescence quenching, redox cycling, aggregation).
• Use PAINS and REOS filters cautiously as heuristics; always validate hits with dose–response curves, reprofiling from a fresh solid aliquot.

Compliance

• This product is designated For research use only. No medical, diagnostic, or clinical claims are made or implied.

Buffer Applications

This product is a small organic molecule and is not a buffering agent. Conventional buffer systems (e.g., phosphate, HEPES, TRIS) are not applicable to this compound as a component.

Practical integration into buffered systems (general)

• Prepare a concentrated stock in DMSO and dilute into the chosen assay buffer to a final DMSO content typically between 0.1–1% v/v, as tolerated by the biology/assay.
• To mitigate precipitation upon dilution, pre-warm the buffer (room temperature), add compound slowly with mixing, and verify clarity.
• For pH-sensitive compounds (unknown here), maintain buffer pH within physiological ranges (6.8–7.6) unless the assay requires otherwise, and avoid buffers that can form adducts (e.g., primary amines in TRIS with acylating agents).
• Filter-sterilize final working solutions when needed, using low-binding filters to minimize adsorption losses.

Note: Specific pKa or ionization behavior is not available; adjust strategies once the structure is known.

Green Alternatives

This listing is a discrete small molecule rather than a commodity solvent or reagent where greener substitutes are typically discussed. Nevertheless, greener practices can be applied to its handling and use.

Greener practice suggestions (general)

• Prefer microscale assays and miniaturized HTS formats (e.g., 384/1536-well) to reduce solvent and compound consumption.
• Use DMSO judiciously; where feasible, select water-miscible greener co-solvents (e.g., ethanol) at low percentages, provided assay tolerance is validated.
• Implement closed-vial or sealed-plate workflows to limit VOC emissions and photodegradation.
• Optimize chromatographic methods to reduce solvent usage: short columns, higher flow with sub-2 µm particles, or SFC where compatible.
• Consolidate shipments on dry ice to minimize logistical footprint while maintaining the cold chain.

Applicability

• Substitution with a different compound is not meaningful in this context because structure and function are compound-specific. Once the chemical class is known, consider greener synthetic routes or alternative scaffolds with improved stability or lower hazard profiles, guided by metrics such as PMI, E-factor, and solvent selection guides.

Pharmaceutical Uses

• Regulatory/compendial status: Not specified for this item; refer to CoA/Spec Sheet.
• Intended use: For research use only. Not for human or veterinary use, clinical diagnostics, or as an API/excipient in GMP manufacture.

Research-phase formulation context (general; not item-specific)

• Early discovery tool compounds are commonly formulated as DMSO stocks for screening, with subsequent evaluation of solubility/stability in biorelevant media only for preclinical research where permitted.
• If solid form and salt state are disclosed later, selection of pharmaceutically acceptable salts (e.g., HCl for bases, Na/K for acids) may be explored during medicinal chemistry campaigns to tune solubility and stability—outside the scope of this specific catalog listing.

Documentation

• No claims regarding pharmacology, safety, efficacy, or dosage are made. For any translational work, obtain full structural data, impurity profiles, and stability information, and follow institutional and regulatory requirements.

Physical Properties

Item-specific physicochemical data are not supplied in the current record.

• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Melting point / Boiling point: Not specified for this item; refer to CoA/Spec Sheet.
• Density: Not specified for this item; refer to CoA/Spec Sheet.
• Refractive index: Not specified for this item; refer to CoA/Spec Sheet.
• Solubility profile (water/organic): Not specified for this item; refer to CoA/Spec Sheet.
• pKa / logP (or logD): Not specified for this item; refer to CoA/Spec Sheet.

General guidance (literature/practice; not item-specific)

• For novel/unknown small molecules, initial solubility screening commonly begins with anhydrous DMSO (10–50 mg/mL stock), followed by dilution into assay buffers (final DMSO 0.1–1% v/v where compatible).
• If the compound is weakly basic: consider acidified aqueous co-solvent systems (e.g., 0.1% TFA or HCl in water/MeCN). If weakly acidic: basic co-solvents (e.g., 0.1% NH4OH) may improve solubility.
• Evaluate stability under light and temperature constraints given the specified storage at −80°C and light protection, which can indicate photosensitivity and/or limited thermal stability.

Always defer to the item’s CoA/SDS for definitive specifications before method development.

Quality & Grades

• Grade/Purity: Not specified for this item; refer to CoA/Spec Sheet.

Context for small-molecule library items (general)

• Library compounds are typically supplied at research grade for hit discovery, assay development, and SAR exploration. Purity is commonly assessed by LC–MS/UPLC and 1H NMR, with a typical internal threshold of ≥90–95% for screening collections; however, no specific threshold is provided for this item.
• Absence of specified stabilizers suggests none are intentionally added, but this is not confirmed. If stabilizers or salt forms are relevant, they will be listed on the CoA.

What to verify on receipt

• Identity: LC–MS (correct [M+H]+/[M−H]−), isotope pattern, retention time vs reference if available.
• Purity: UPLC area % at multiple wavelengths (e.g., 210/254/280 nm) to profile UV-absorbing impurities.
• Residual solvents and water content: Karl Fischer and GC headspace when methods are sensitive to moisture/volatiles.
• Solid-state form: salt/counterion, polymorph/amorphous—if applicable to your downstream work.

Documentation

• For any method qualification or regulated workflows, request the latest CoA/Spec Sheet and stability statement. This product is designated For research use only and is not intended for diagnostic or GMP manufacturing.

Reaction & Applications

This product is listed within a small-molecule/compound library category and is primarily intended for discovery research and screening. No specific reactivity profile or functional-group information is available.

Research applications (general; not item-specific)

• High-throughput screening (HTS), fragment or lead-like screening depending on MW and scaffold class.
• Biochemical/biophysical assay development: binding studies, thermal shift assays (DSF), biolayer interferometry (BLI), SPR—subject to solubility and assay compatibility.
• Phenotypic screening in cell-based models at low DMSO percentages, with orthogonal counterscreens to assess specificity and cytotoxicity.
• Early SAR exploration and analogue prioritization once structure is known.

Analytical considerations

• Establish a robust reference chromatographic method (e.g., UPLC, C18, water/MeCN with 0.1% formic acid) to evaluate purity and stability under assay conditions.
• Monitor compound integrity under light exposure due to the storage requirement “protected from light.”

Note

• Without a disclosed structure, synthetic transformations, named reactions, and mechanistic applications cannot be specified. For custom chemistry or hit expansion, obtain the structural information, salt form, and stereochemistry from the CoA or through analytical elucidation.

Reaction Conditions

Specific reaction conditions cannot be provided without knowledge of the compound’s functional groups and reactivity.

General laboratory handling for solutions (not item-specific)

• Reconstitution at room temperature in dry DMSO, followed by immediate aliquoting and storage at −80°C.
• Avoid prolonged exposure to light; handle in low-light conditions or with amber glassware.
• For stability studies, design a small DoE varying temperature (−20, 4, 25°C), light (dark/ambient), and pH (if aqueous) to map degradation pathways prior to extended assays.

If derivatization is intended (after structure disclosure)

• Choose conditions typical for the identified functional groups (e.g., base-catalyzed amide coupling for acids, Pd-catalyzed cross-coupling for aryl halides, reductive amination for carbonyl/amine pairs), and validate with small-scale scouting reactions.

Safety & Handling

Item-specific hazard data are not provided in the current listing.

• GHS classification: Not specified for this item; refer to SDS.
• Signal word / H-statements / Pictograms: Not specified for this item; refer to SDS.

Known storage and transport conditions (from Product Data)

• Storage: Store at −80°C, protected from light.
• Shipping: Dry ice packs + cold packs (maintain low temperature; minimize thaw events).

General laboratory precautions (best practice; not item-specific)

• Handle inside a chemical fume hood. Avoid inhalation, ingestion, and skin/eye contact.
• Wear appropriate PPE: lab coat, nitrile gloves, and splash-resistant safety glasses; upgrade to chemical-resistant gloves and face protection for scale-up or aerosol-generating steps.
• Avoid exposure to light during handling and storage (wrap containers in foil or use amber vials) due to stated light sensitivity.
• Use only dry, compatible solvents for reconstitution; moisture can catalyze degradation for some chemotypes.
• Segregate from strong oxidizers/reductants and reactive acids/bases until specific incompatibilities are known.

First-aid overview (consult SDS for authoritative guidance)

• Skin/eye contact: Rinse with water for ≥15 minutes; remove contaminated clothing; seek medical attention.
• Inhalation: Move to fresh air; support respiration if needed; obtain medical attention.
• Ingestion: Rinse mouth; do not induce vomiting unless directed by medical personnel; seek medical attention.

Waste disposal

• Collect as hazardous chemical waste; incinerate or dispose per institutional and local regulations. Reference SDS for proper waste codes.

Solvent Selection

Because no structural or polarity data are provided, initial solvent selection should prioritize broad compatibility with drug-like small molecules.

Recommended approach (general; not item-specific)

• Primary stock solvent: Anhydrous DMSO (e.g., 10–50 mg/mL). Filter-sterilize if required for biological assays.
• Secondary options: DMF, acetonitrile, ethanol or methanol for less hydrophobic scaffolds; 2-methyltetrahydrofuran (2-MeTHF), MTBE, or EtOAc for nonpolar species (for processing, not bioassays).
• Aqueous work: Use co-solvent systems (DMSO 5–20% v/v) and surfactants where acceptable (e.g., 0.01–0.1% Tween-80) to minimize precipitation; verify assay tolerance.

Miscibility and dielectric notes (literature/general)

• DMSO is fully miscible with water and most organic solvents and offers excellent solvency for diverse chemotypes.
• Acetonitrile provides low viscosity and UV transparency, useful for LC methods.

Small comparison (general)

• DMSO vs DMF: DMSO is generally less volatile and widely accepted in bioassays; DMF may offer improved solubility for certain polar/ionic species but can be less tolerated biologically.
• EtOH/MeOH: convenient for quick screening but may impact enzyme/cell assays at >1–2% v/v.

Practical tips

• Prepare aliquots to avoid repeated freeze–thaw of concentrated stocks.
• Verify clarity after dilution into assay buffer; inspect for nano-precipitation by DLS or plate-based turbidity if critical.

Storage & Reconstitution

Item-specific conditions (from Product Data)

• Storage: Store at −80°C, protected from light.
• Shipping: Dry ice packs + Cold packs to maintain the cold chain.

Best practices (general; not item-specific)

• Upon receipt: Keep frozen. Allow the outer container to equilibrate to room temperature before opening to minimize condensation. Maintain the primary vial at low temperature and protected from light (foil-wrap/amber vial).
• Aliquoting: If a solid, subdivide quickly under low light, inert atmosphere if feasible. If a solution, prepare single-use aliquots to avoid repeated freeze–thaw.
• Reconstitution: Start with anhydrous DMSO to prepare a concentrated stock (e.g., 10–50 mg/mL), then dilute into assay buffer immediately prior to use. Final solvent systems should be validated for clarity and stability.
• Stability: Minimize exposure to ambient temperature and light during handling. Track cumulative freeze–thaw cycles; discard aliquots showing precipitation, discoloration, or unexpected LC–MS profiles.
• Documentation: Record reconstitution solvent, concentration, date, and storage location; affix light-sensitive labeling.

Item-specific details such as solubility limits, solution stability, and exact concentration ranges are not specified for this item; refer to CoA/Spec Sheet.

Structure & Identity

• Item name/SKU: M435-1279 (SKU: M649720)
• CAS: 1359431-16-5
• Category: Small molecules and compound libraries (screening collection)

Item-specific identifiers and structure

• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• SMILES: Not specified for this item; refer to CoA/Spec Sheet.
• InChIKey: Not specified for this item; refer to CoA/Spec Sheet.

Structural features (general notes)

• 2D/3D structure, functional groups, ring systems, and stereochemistry are not provided in the current product data. Without a structural representation (SMILES/InChI), detailed functional-group commentary cannot be given.
• If structural information becomes available, include: core scaffold (e.g., heteroaromatic vs aliphatic), heteroatom content (N/O/S/halogens), stereocenters, and potential ionizable sites—these features govern solubility, pKa, logP, and selection of assay solvents.

Documentation

• For definitive identity confirmation, consult the product’s Certificate of Analysis (CoA) and any accompanying spectral data (NMR, LC–MS, HRMS) provided on request. Where available, match CAS 1359431-16-5 against internal reference spectra prior to use in screening campaigns.

Synthetic Utility

No structural or functional-group information is provided for this compound; therefore, specific synthetic roles or transformations cannot be assigned.

General guidance when structure becomes available (not item-specific)

• Identify key functional handles (e.g., aryl halides, boronates, aldehydes, amines, acids) to plan cross-couplings (Suzuki–Miyaura, Buchwald–Hartwig), condensations, reductions/oxidations, or late-stage functionalization.
• Assess protecting-group needs, chemoselectivity, and orthogonality if multiple reactive sites are present.
• For chiral molecules, determine absolute configuration and consider enantioselective synthesis or resolution.

Analytical support

• Use LC–MS reaction monitoring, orthogonal purity assessment (UPLC-UV/ELSD), and stability-indicating methods to guide any derivatization or analogue synthesis.

Until the structure is disclosed, treat this item as a finished small molecule intended for screening rather than as a synthetic building block.

Target Specificity

Target/epitope specificity is not applicable. This product is a small molecule (not an antibody, protein, or nucleic acid).

• Known biological target(s): Not specified for this item; refer to CoA/Spec Sheet or screening results generated by the end user.
• If used in target validation workflows, pair with orthogonal assays (binding and function) to characterize selectivity across related protein families once a putative target is identified.